IL2 and systemic lupus erythematosus: Another clinical study in refractory SLE patients reported that the SLEDAI scores (a disease activity index for lupus patients) were significantly lowered with low dose IL-2 and rapamycin treatment and normalization of TH17/Treg ratios were significantly reduced (Zhao et al., 2019b).